27
https://pubmed.ncbi.nlm.nih.gov/38114938
The novel surgical approach for advanced HCC with portal vein tumor thrombus (PVTT) following combination therapy of tyrosine kinase inhibitors (TKIs) and programmed cell death protein 1 (PD-1) inhibitors shows favorable long-term survival and portal vein patency.